Literature DB >> 19558415

alpha-MSH tripeptide analogs activate the melanocortin 1 receptor and reduce UV-induced DNA damage in human melanocytes.

Zalfa A Abdel-Malek1, Andrew Ruwe, Renny Kavanagh-Starner, Ana Luisa Kadekaro, Viki Swope, Carrie Haskell-Luevano, Leonid Koikov, James J Knittel.   

Abstract

One skin cancer prevention strategy that we are developing is based on synthesizing and testing melanocortin analogs that reduce and repair DNA damage resulting from exposure to solar ultraviolet (UV) radiation, in addition to stimulating pigmentation. Previously, we reported the effects of tetrapeptide analogs of alpha-melanocortin (alpha-MSH) that were more potent and stable than the physiological alpha-MSH, and mimicked its photoprotective effects against UV-induced DNA damage in human melanocytes. Here, we report on a panel of tripeptide analogs consisting of a modified alpha-MSH core His(6)-d-Phe(7)-Arg(8), which contained different N-capping groups, C-terminal modifications, or arginine mimics. The most potent tripeptides in activating cAMP formation and tyrosinase of human melanocytes were three analogs with C-terminal modifications. The most effective C-terminal tripeptide mimicked alpha-MSH in reducing hydrogen peroxide generation and enhancing nucleotide excision repair following UV irradiation. The effects of these three analogs required functional MC1R, as they were absent in human melanocytes that expressed non-functional receptor. These results demonstrate activation of the MC1R by tripeptide melanocortin analogs. Designing small analogs for topical delivery should prove practical and efficacious for skin cancer prevention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19558415     DOI: 10.1111/j.1755-148X.2009.00598.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  35 in total

Review 1.  Paracrine regulation of melanocyte genomic stability: a focus on nucleotide excision repair.

Authors:  Stuart Gordon Jarrett; Katharine Marie Carter; John August D'Orazio
Journal:  Pigment Cell Melanoma Res       Date:  2017-04-20       Impact factor: 4.693

2.  Brazilian consensus on photoprotection.

Authors:  Sérgio Schalka; Denise Steiner; Flávia Naranjo Ravelli; Tatiana Steiner; Aripuanã Cobério Terena; Carolina Reato Marçon; Eloisa Leis Ayres; Flávia Alvim Sant'anna Addor; Helio Amante Miot; Humberto Ponzio; Ida Duarte; Jane Neffá; José Antônio Jabur da Cunha; Juliana Catucci Boza; Luciana de Paula Samorano; Marcelo de Paula Corrêa; Marcus Maia; Nilton Nasser; Olga Maria Rodrigues Ribeiro Leite; Otávio Sergio Lopes; Pedro Dantas Oliveira; Renata Leal Bregunci Meyer; Tânia Cestari; Vitor Manoel Silva dos Reis; Vitória Regina Pedreira de Almeida Rego
Journal:  An Bras Dermatol       Date:  2014 Nov-Dec       Impact factor: 1.896

Review 3.  Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.

Authors:  Joanne M Jeter; Tawnya L Bowles; Clara Curiel-Lewandrowski; Susan M Swetter; Fabian V Filipp; Zalfa A Abdel-Malek; Larisa J Geskin; Jerry D Brewer; Jack L Arbiser; Jeffrey E Gershenwald; Emily Y Chu; John M Kirkwood; Neil F Box; Pauline Funchain; David E Fisher; Kari L Kendra; Ashfaq A Marghoob; Suephy C Chen; Michael E Ming; Mark R Albertini; John T Vetto; Kim A Margolin; Sherry L Pagoto; Jennifer L Hay; Douglas Grossman; Darrel L Ellis; Mohammed Kashani-Sabet; Aaron R Mangold; Svetomir N Markovic; Frank L Meyskens; Kelly C Nelson; Jennifer G Powers; June K Robinson; Debjani Sahni; Aleksandar Sekulic; Vernon K Sondak; Maria L Wei; Jonathan S Zager; Robert P Dellavalle; John A Thompson; Martin A Weinstock; Sancy A Leachman; Pamela B Cassidy
Journal:  Cancer       Date:  2018-10-03       Impact factor: 6.860

Review 4.  Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.

Authors:  Elisabeth I Minder; Jasmin Barman-Aksoezen; Xiaoye Schneider-Yin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

5.  Melanocyte-stimulating hormone directly enhances UV-Induced DNA repair in keratinocytes by a xeroderma pigmentosum group A-dependent mechanism.

Authors:  Liang Dong; Ji Wen; Eric Pier; Xiao Zhang; Bo Zhang; Fangzheng Dong; Nick Ziegler; Margaret Mysz; Rafael Armenta; Rutao Cui
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

6.  Divergence of cAMP signalling pathways mediating augmented nucleotide excision repair and pigment induction in melanocytes.

Authors:  Erin M Wolf Horrell; Stuart G Jarrett; Katharine M Carter; John A D'Orazio
Journal:  Exp Dermatol       Date:  2017-04-21       Impact factor: 3.960

Review 7.  Roles of UVA radiation and DNA damage responses in melanoma pathogenesis.

Authors:  Aiman Q Khan; Jeffrey B Travers; Michael G Kemp
Journal:  Environ Mol Mutagen       Date:  2018-02-21       Impact factor: 3.216

Review 8.  Hormonal Regulation of the Repair of UV Photoproducts in Melanocytes by the Melanocortin Signaling Axis.

Authors:  Stuart G Jarrett; John A D'Orazio
Journal:  Photochem Photobiol       Date:  2016-11-17       Impact factor: 3.421

Review 9.  MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation.

Authors:  Jose C García-Borrón; Zalfa Abdel-Malek; Celia Jiménez-Cervantes
Journal:  Pigment Cell Melanoma Res       Date:  2014-05-30       Impact factor: 4.693

Review 10.  UVA tanning is involved in the increased incidence of skin cancers in fair-skinned young women.

Authors:  Sergio G Coelho; Vincent J Hearing
Journal:  Pigment Cell Melanoma Res       Date:  2009-12-02       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.